Accelerated Treatment of Endocarditis
NCT05144399 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 475
Last updated 2024-01-18
Summary
Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks one or more types of intravenously administered antibiotics. The long hospitalization increases several risks for the patient, including mental strain and increased loss of function. Furthermore, it poses a significant financial burden on the health systems. Current guidelines fail to use available clinical and paraclinical, data collected from patients (echo, temperature, CRP, leukocytes, procalcitonin etc.) to determine duration of treatment. A strategy including these data in treatment algorithms ensures an individualized treatment, targeting the individual patient's course and response to treatment. Thus, the purpose of this open-label, prospective, non-inferiority, RCT study is to investigate the safety and effectiveness of shortening treatment of endocarditis based on the individual patient's initial treatment response, sampling 475 patients, approx. 125 patients with each type of bacteria (Streptococci; Enterococcus faecalis; Staphylococcus aureus).
Conditions
- Endocarditis
Interventions
- OTHER
-
Accelerated antibiotic treatment
E. faecalis uncomplicated: 4 weeks. E. faecalis complicated: 4 weeks. S. aureus uncomplicated: 2 weeks. S. aureus complicated: 4 weeks. Streptococci spp. NVE: 2 weeks. Streptococci spp. PVE or abscess: 3 weeks. Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received. Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery. Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE. NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.
- OTHER
-
Standard treatment length
E. faecalis uncomplicated: 6 weeks. E. faecalis complicated: 6 weeks. S. aureus uncomplicated: 4 weeks. S. aureus complicated: 6 weeks. Streptococci spp. NVE: 4 weeks. Streptococci spp. PVE or abscess: 6 weeks. Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received. Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery. Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE. NVE: native valve endocarditis, PVE: prosthetic valve endocarditis.
Sponsors & Collaborators
-
Herlev Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-01
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Denmark
Study Locations
More Related Trials
-
Antibiotic Resistance in Danish EDs.
NCT03352167 ·Status: COMPLETED
-
Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood
NCT02482051 ·Status: COMPLETED
-
Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock
NCT06006754 ·Status: COMPLETED
-
Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection
NCT02000414 ·Status: COMPLETED ·Phase: NA
-
Treatment of Bacterial Vaginosis
NCT00324818 ·Status: COMPLETED ·Phase: PHASE4
-
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
NCT05148702 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital
NCT04577989 ·Status: COMPLETED
-
Support Tool for Antibiotic Allergy deLabeling
NCT06771440 ·Status: RECRUITING ·Phase: NA
-
Short vs Long of Usual Treatment for Non Complicated Enterococcal Bacteremia
NCT05394298 ·Status: UNKNOWN ·Phase: PHASE4
-
Biofilms on Short-term Indwelling Ureteral Stents
NCT02845726 ·Status: COMPLETED
-
Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis
NCT03153384 ·Status: COMPLETED
-
Personalized Medicine in Patients With Infective Endocarditis
NCT04838938 ·Status: COMPLETED
-
The Role of Polymerase Chain Reaction in the Management of Patients With Infective Endocarditis
NCT05791357 ·Status: COMPLETED ·Phase: NA
-
CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit
NCT06260345 ·Status: RECRUITING
-
Etiology of Endocarditis in Negative Blood Cultures
NCT02816307 ·Status: COMPLETED ·Phase: NA
-
Amplification and Selection of Antimicrobial Resistance in the Intestine
NCT02058888 ·Status: COMPLETED
-
Management of Infectious Endocarditis as Part of a Multidisciplinary Consensus Meeting
NCT03429153 ·Status: UNKNOWN
-
Evaluation of Antibiotherapy Prescribed for Outpatients From Emergency Departments
NCT05350995 ·Status: UNKNOWN
-
Retrospective Review of Management of Infective Endocarditis
NCT00579761 ·Status: WITHDRAWN
-
Impact of Prolonged Antibiotic Therapy on Commensal Microbial Community Gene Expression.
NCT05169255 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)
NCT00379951 ·Status: COMPLETED ·Phase: PHASE3
-
Community-associated Highly-Resistant Enterobacterales
NCT03924934 ·Status: COMPLETED
-
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives
NCT03250104 ·Status: COMPLETED
-
Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals
NCT02007343 ·Status: COMPLETED
-
Real-world Multicentre Study of AZtreonam-AVIbactam Treatment With Infections or Suspected Infections Caused by Multidrug-resistant Gram-negative Bacteria
NCT07176247 ·Status: ENROLLING_BY_INVITATION